GlaxoSmithKline plc didn’t stop at reporting sales declines across nearly all consumer health product categories in its first-quarter results. The UK pharma also reminded analysts and investors that it’s on schedule for moving its consumer health segment to a separate business.
Against an unfavorable comparison to sales driven by COVID-19-related stockpiling in the year-ago period and with a weak cold and flu season slowing consumer health product sales in the January-March period, sales for GSK’s